Study shows that patients older than 80 years benefit from immunotherapy

O’Rourke, Kate

doi:10.1002/cncr.34138

Cited by 2 publications

(1 citation statement)

References 1 publication

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, several authors propose the use of neo-adjuvant hormonotherapy to evaluate the response to hormonal therapeutics in the patient, this option should be extended in clinical practice [43,44]. Moreover, immunotherapy can benefit elderly patients, but they also had higher adverse effects and stopped treatment earlier than younger patients [45]. The toxicity of chemotherapy in addition to complications during treatment and difficulty in completing treatment in full, is associated with loss of years of life due to its negative effects of it [45][46][47], due to the even if not age-related comorbidities and reduction in organ function, elderly individuals have a lower tolerance for chemotherapy as compared to younger patients [48].…”

Section: Introductionmentioning

confidence: 99%

Geriatric Breast Cancer: Staging, Molecular Surrogates, and Treatment. A Review & Meta-analysis

Fonseca,

Sidiropoulou

2023

Aging and disease

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most frequent cancers in females across the globe. Treatment recommendations for BC patients are primarily driven by patient age, staging and tumor molecular subtype. Thus, we updated the general overview of BC staging, molecular surrogates, and treatment choices for women >70 years based on a systematic study encompassing the years 2013-2023. A PRISMA guidelines and PICO framework were followed, and relevant research articles were searched using different data bases (Web of Sciences, PubMed, MEDLINE, and Scopus). Mixed Methods Appraisal Tool was used for studies quality assessment. The research articles that made it into the systematic review were compiled using qualitative criteria. In the meanwhile, heterogeneity was determined using meta-analysis with RevMan 5.4. We applied a random effects model with a 0.05 significance level. Overall, there were 4151 research articles, after screening only 17 articles with 39,906 patients were included. Conclusion: Elderly patients with breast cancer should be treated differently in an adapted way. The treatment should not be the same worldwide due to different health systems. Molecular surrogates are different in geriatric patients. Surgery is the best option for treatment in this subset of patients. We need to have therapeutic decision appointments for elderly patients with breast cancer. The guidelines and medical authority should be used in the best decision.

show abstract

Section: Introductionmentioning

confidence: 99%

Geriatric Breast Cancer: Staging, Molecular Surrogates, and Treatment. A Review & Meta-analysis

Fonseca,

Sidiropoulou

2023

Aging and disease

View full text Add to dashboard Cite

show abstract

Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients

Al-Danakh,

Safi,

Jian

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Older patients with cancer, particularly those over 75 years of age, often experience poorer clinical outcomes compared to younger patients. This can be attributed to age-related comorbidities, weakened immune function, and reduced tolerance to treatment-related adverse effects. In the immune checkpoint inhibitors (ICI) era, age has emerged as an influential factor impacting the discovery of predictive biomarkers for ICI treatment. These age-linked changes in the immune system can influence the composition and functionality of tumor-infiltrating immune cells (TIICs) that play a crucial role in the cancer response. Older patients may have lower levels of TIICs infiltration due to age-related immune senescence particularly T cell function, which can limit the effectivity of cancer immunotherapies. Furthermore, age-related immune dysregulation increases the exhaustion of immune cells, characterized by the dysregulation of ICI-related biomarkers and a dampened response to ICI. Our review aims to provide a comprehensive understanding of the mechanisms that contribute to the impact of age on ICI-related biomarkers and ICI response. Understanding these mechanisms will facilitate the development of treatment approaches tailored to elderly individuals with cancer.

show abstract

Study shows that patients older than 80 years benefit from immunotherapy

Abstract: in patient out-of-pocket costs, which reflected differences in treatment intensity and duration as well as survival. Phasespecific costs were the highest for patients with acute myeloid leukemia (AML), myeloma, brain cancer, and pancreatic cancer.

Cited by 2 publications

References 1 publication

Geriatric Breast Cancer: Staging, Molecular Surrogates, and Treatment. A Review & Meta-analysis

Geriatric Breast Cancer: Staging, Molecular Surrogates, and Treatment. A Review & Meta-analysis

Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients

Contact Info

Product

Resources

About